Hansa Biopharma AB

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:01 17/07/2024 pm IST			5-day change	1st Jan Change
46.56 ^SEK	-4.51%		-9.15%	+77.71%

27/06	Hansa Biopharma AB Announces Board Appointments	CI
31/05	Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial	MT

Hansa Medical AB(OM:HMED) dropped from OMX Nordic Small Cap Index

January 09, 2017 at 10:30 am IST

Hansa Medical AB has been removed from OMX Nordic Small Cap Index.

Latest news about Hansa Biopharma AB

Hansa Biopharma AB Announces Board Appointments	27/06	CI
Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial	31/05	MT
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial	31/05	CI
Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting	21/05	CI
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04	CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04	MT
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04	CI
Hansa Biopharma Hires New CFO	22/02	MT
Hansa Biopharma AB Announces CFO Changes	22/02	CI
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02	CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02	CI
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01	CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	06/01	CI
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation	15/12	CI
Hansa Biopharma Nomination Committee Formed	13/12	CI
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial	07/12	CI
Hansa Biopharma Expects Up to SEK85 Million Annual Savings from Workforce Reduction Plan	05/12	MT
Hansa Biopharma Plans Restructuring to Strengthen Long-Term Competitiveness and Advance Key Deliverables	05/12	CI
Sweden's Hansa Biopharma CFO to Depart in February 2024	27/11	MT
Hahansa Biopharma AB Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024	27/11	CI
Transcript : Hansa Biopharma AB, Nine Months 2023 Earnings Call, Oct 26, 2023	26/23/26
Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients	17/23/17	MT

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Companyâs operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeSâs goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Companyâs patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

18/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hansa Biopharma AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

48.76 SEK

Average target price

105 SEK

Spread / Average Target

+115.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANSA BIOPHARMA AB	+77.71%	31Cr
MODERNA, INC.	+23.91%	4.8TCr
IQVIA HOLDINGS INC.	+0.20%	4.24TCr
LONZA GROUP AG	+43.96%	4.15TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.87%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+19.48%	2.86TCr
CELLTRION, INC.	-4.47%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+51.39%	1.46TCr
MEDPACE HOLDINGS, INC.	+44.08%	1.41TCr
BIO-TECHNE CORPORATION	+1.94%	1.26TCr

Other Biotechnology & Medical Research

Hansa Biopharma AB

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Hansa Medical AB(OM:HMED) dropped from OMX Nordic Small Cap Index

Latest news about Hansa Biopharma AB

Chart Hansa Biopharma AB

Company Profile

Income Statement Evolution

Ratings for Hansa Biopharma AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research